Babu Yarlagadda S's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Mar 9, 2022
- Accession no.
- 0001127602-22-008780
- Filed
- Mar 9, 2022
- Trade date
- Mar 7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $343.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Babu Yarlagadda SCIK 0001452635 | Officer (Chief Discovery Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2022 | Common Stock | SSaleDisposed | −20,000 | $17.16 | −$343,200 | 230,056 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.